

1-[[3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl]-methyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine

Hai-Bo Wang,* Zhi-Qian Liu and Xiao-Chen Yan

Department of Applied Chemistry, College of Science, Nanjing University of Technology, Ximofan Road No.5 Nanjing, Nanjing 210009, People's Republic of China

Correspondence e-mail: wanghaibo@njut.edu.cn

Key indicators

Single-crystal X-ray study
 $T = 293$ K
 Mean $\sigma(\text{C}-\text{C}) = 0.014$ Å
 R factor = 0.090
 wR factor = 0.264
 Data-to-parameter ratio = 14.1

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


The title compound, $\text{C}_{23}\text{H}_{26}\text{BrN}_5\text{O}_2$, was synthesized by the reaction of 4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and 3-(3-nitrophenyl)-5-chloromethyl-1,2,4-oxadiazole. There are intramolecular $\text{C}-\text{H}\cdots\text{N}$ and intermolecular $\text{N}-\text{H}\cdots\text{O}$ and $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds in the crystal structure.

Received 3 July 2006

Accepted 19 July 2006

Comment

Piperazine derivatives are of great interest because of their biological properties. Some derivatives of piperazine have antifilarial, anti-amoebic and spermicidal properties (Sonurlikar *et al.*, 1977). Some show high efficacy in preventing neuronal damage or stimulating nerve growth (Tomlinson *et al.*, 2004). Some are used to treat psychosis and bipolar disorders (Aicher *et al.*, 2004) or are neurokinin antagonists (Janssens *et al.*, 2004).



The molecular structure of the title compound, (I), is shown in Fig. 1. The crystal packing is stabilized by $\text{C}-\text{H}\cdots\text{N}$, $\text{N}-\text{H}\cdots\text{O}$ and $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds (Table 1).

Experimental

4-[(2,6-Dimethylphenyl)aminocarbonylmethyl]piperazine (20 mmol) and 3-phenyl-5-chloromethyl-1,2,4-oxadiazole (20 mmol) were dissolved in anhydrous ethanol (80 ml). The resulting mixture was refluxed for 6 h. Subsequent concentration of the mixture under reduced pressure afforded the crude compound. Pure compound (I) was obtained by recrystallization from ethyl acetate. Crystals of (I) suitable for X-ray diffraction were obtained by slow evaporation of an ethanol solution.

Crystal data

C₂₃H₂₆BrN₅O₂
M_r = 484.40
 Monoclinic, *P*2₁/*c*
a = 7.2000 (14) Å
b = 9.5300 (19) Å
c = 33.089 (7) Å
 β = 94.71 (3)°
V = 2262.8 (8) Å³

Z = 4
D_x = 1.422 Mg m⁻³
 Mo Kα radiation
 μ = 1.85 mm⁻¹
T = 293 (2) K
 Block, colourless
 0.30 × 0.30 × 0.10 mm

Data collection

Enraf–Nonius CAD-4
 diffractometer
 ω/2θ scans
 Absorption correction: ψ scan
 (North *et al.*, 1968)
T_{min} = 0.607, *T_{max}* = 0.837
 4309 measured reflections

3966 independent reflections
 2155 reflections with *I* > 2σ(*I*)
R_{int} = 0.105
 θ_{max} = 25.0°
 3 standard reflections
 every 200 reflections
 intensity decay: 3%

Refinement

Refinement on *F*²
R[*F*² > 2σ(*F*²)] = 0.090
wR(*F*²) = 0.264
S = 0.97
 3966 reflections
 281 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.1P)^2 + 21P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 (Δ/σ)_{max} = 0.001
 Δρ_{max} = 1.24 e Å⁻³
 Δρ_{min} = -0.45 e Å⁻³
 Extinction correction: *SHELXL97*
 (Sheldrick, 1997)
 Extinction coefficient: 0.015 (2)

Table 1

Hydrogen-bond geometry (Å, °).

<i>D</i> —H... <i>A</i>	<i>D</i> —H	H... <i>A</i>	<i>D</i> ... <i>A</i>	<i>D</i> —H... <i>A</i>
N1—H1A...O1 ⁱ	0.86	2.21	3.047 (9)	163
C7—H7A...N1	0.96	2.45	2.909 (12)	109
C8—H8A...N1	0.96	2.33	2.825 (12)	111
C10—H10B...O1 ⁱ	0.97	2.55	3.309 (10)	135
C23—H23A...N5	0.93	2.49	2.816 (13)	101

Symmetry code: (i) $-x + 1, y + \frac{1}{2}, -z + \frac{3}{2}$.

All H atoms bonded to the C atoms were positioned geometrically, with C—H distances in the range 0.93–0.96 Å, and they were included in the refinement in a riding-model approximation, with *U*_{iso}(H) = 1.2 or 1.5*U*_{eq}(C). The N-bound H atom was also positioned geometrically and refined as riding, with N—H = 0.86 Å and with *U*_{iso}(H) = 1.2*U*_{eq}(N).

Data collection: *CAD-4 Software* (Enraf–Nonius, 1989); cell refinement: *CAD-4 Software*; data reduction: *XCAD4* (Harms & Wocadlo, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Siemens, 1996); software used to prepare material for publication: *SHELXL97*.




Figure 1

A view of the molecular structure of (I). Displacement ellipsoids are drawn at the 30% probability level.

References

- Aicher, T. D., Chen, Z., Le Huerou, Y., Martin, F. M., Pineiro-Nunez, M. M., Rocco, V. P., Ruley, K. M., Schaus, J. M., Spinazze, P. G. & Tupper, D. (2004). World Patent WO 2004014895.
 Enraf–Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf–Nonius, Delft, The Netherlands.
 Harms, K. & Wocadlo, S. (1995). *XCAD4*. University of Marburg, Germany.
 Janssens, F. E., Sommen, F. M., De Boeck, B. C. A. G., Leenaerts, J. E., Van Roosbroeck, Y. E. M. & Diels, G. S. M. (2004). World Patent WO 2004033428.
 North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
 Sheldrick, G. M. (1997). *SHELXL97* and *SHELXS97*. University of Göttingen, Germany.
 Siemens (1996). *SHELXTL*. Version 5.06. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
 Sonurlikar, U. A., Shanker, B., Kirke, P. A. & Bhide, M. B. (1977). *Bull. Haffkine Inst.* **5**, 94–96.
 Tomlinson, R., Lauffer, D. & Mulican, M. (2004). US Patent 2004034019.